

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

**SUPPLEMENTAL ANNOUNCEMENT
RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF EXECUTIVE
OFFICER AND CHIEF TECHNOLOGY OFFICER**

Reference is made to the announcement of the Company dated 30 May 2025 (the “**Announcement**”) in relation to the resignation of Dr Wang as an executive Director, CEO and CTO with effect from 25 June 2025. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, it was stated that Dr Wang’s resignation was due to certain disagreements with the Board. The Board would like to provide the following additional details on the disagreements and the basis of the Directors’ view that the allegations in her resignation letter were without merit. Regarding her allegation on the provisions under the internal control and management authority, while her employment contract includes her responsibilities of managing the Company’s daily operation and formulating and implementing its overall strategy and business plan, the Company’s recent internal control enhancement, which includes a provision that its management personnel cannot approve their own expense reimbursements, aims to promote good corporate governance and does not infringe upon her authority as CEO in any material aspects. Regarding her allegation on a Director who has been living aboard, such Director ordinarily resides in Hong Kong and has been effectively performing his duties, including chairing all Board meetings and communicating with individual Directors as needed. Accordingly, the Board is not aware of any inappropriate interference by him with the Company’s operations as at the date of this announcement. Regarding her allegation on the two Directors no longer representing the interests of any shareholders of the Company (the “**Shareholders**”) due to a change of ownership, there are no provisions in the Company’s corporate governance or internal control guidelines requiring Directors to represent the interests of certain Shareholder(s). The Board regularly reviews its composition by considering factors such as the diversity of the Board and experience, knowledge and skills of each Director, and will make appropriate adjustments considering the actual circumstances. Regarding her allegation on the Board’s governance failure, the Board has been constantly monitoring the Company’s operations to ensure that the Company adheres to the corporate governance measures in place and is not aware of any failure in its governance causing divergence from the Company’s vision.

Considering the above and to the best knowledge, information and belief of each of the remaining Directors (including the three Directors being named in Dr Wang's resignation letter, namely Mr Tan Zheng, Mr Wang Ruihua and Mr Yang Fan), the Board is of the view that the allegations made in her resignation letter were unfounded and without merit.

All information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 25 June 2025

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Ms Yu Xiaohui, Mr Wang Ruihua, Mr Yang Fan and Mr Wang Donghu as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.